Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all news
4.29.2011

Studies Confirm Link Use of Birth Control Pills Like Yaz and Yasmin to Increased Risk of Injury

Medical researchers from the British Medical Journal have published two more studies confirming the unusually high risks associated with “fourth generation” birth control pills like Yaz and Yasmin that contain the progestin drospirenone.

In the first study, researchers from the Boston University School of Medicine examined two groups of women: one taking Yaz or Yasmin (which both contain drospirenone) and one taking second generation birth control pills (which contain the progestin levonorgestrel). What the authors found is that women who used Yasmin and Yaz were two times as likely to suffer from deep vein thromboses or pulmonary embolisms (blood clots) when compared to users of second generation birth control pills. The authors concluded “[t]hese findings support more recent studies that suggest that drospirenone oral contraceptives are not as safe,” and even recommended that Yasmin and Yaz “should not be the first choice in oral contraception.”

The second study also performed a comparative review of second and third generation birth control users, but this one was based on the information available in the UK General Practice Research Database. Here, the authors found that women who used Yaz and Yasmin were up to three times more likely to suffer from pulmonary embolisms or deep vein thromboses than women who took second generation birth control pills. These results are not only consistent with previous research, but the study excluded individuals with major risk factors for developing blood clots were excluded from the study. Indeed, the authors not only called for more research into the side-effects of drosperinone but they also concluded that third generation birth control pills like Yaz and Yasmin should be avoided since there is no clear evidence that drugs like Yaz and Yasmin provide any benefit when compared to second generation birth control pills.

For more information about the Yazmin case, please click here.

Sources:

First Study

Second Study

Share

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP